Results for “side-effects”

Use when making changes to existing systems to ensure those changes don't break existing functionality. This skill provides procedures for identifying at-risk areas, adding regression tests, and validating changes don't cause unintended side effects.

Implement signal-based reactive state management in Angular v20+. Use for creating reactive state with signal(), derived state with computed(), dependent state with linkedSignal(), and side effects with effect(). Triggers on state management questions, converting from BehaviorSubject/Observable patterns to signals, or implementing reactive data flows.

Advises against testosterone therapy in men with biochemical recurrence after prostate cancer treatment due to very limited data and potential risk of progression. Consider when a patient has a rising PSA after definitive therapy and the clinician evaluates testosterone for hypogonadism, questioning whether TTh is safe in BCR.

Identifies common React useEffect anti-patterns and provides corrected implementations using derived state, event handlers, and cleanup functions.

Think through the consequences of consequences — not just what happens immediately, but what happens next, and next after that, across time. Load when a decision looks obviously good or obviously bad on initial read, when the user is optimising for a short-term outcome that might create a long-term problem, when unintended consequences are a concern, or when deep-thinking diagnoses a second-order frame. Triggers on "what are the downstream effects", "what happens after that", "unintended consequences", "think ahead on this", "long-term vs short-term", or "what comes after that". Based on Howard Marks second-level thinking and Farnam Street mental models. Most powerful for decisions with delayed consequences or systemic effects.

Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA therapy and asking 'Which MRA should I prescribe?' or considering switching agents due to adverse effects, cost, or need for potassium supplementation.

Meta-skill codifying the no-wakeup-polling pattern. Describes the ScheduleWakeup anti-pattern, the fix (--auto merge + detached watcher), and when to still use wakeups. Reduces handoff spam by 80%.

Structure a decision into steelmanned, impact-weighted pros and cons - irreversible consequences flagged, the decisive unknown named, and a clear recommendation you can reject.

Determines whether to recommend unilateral laparoscopic adrenalectomy or medical therapy with a mineralocorticoid receptor antagonist for patients with confirmed unilateral PA (aldosterone-producing adenoma or unilateral adrenal hyperplasia). Triggered when discussing treatment options after confirming unilateral PA in a hypertensive patient with hypokalemia or resistant hypertension.

Recommends mineralocorticoid receptor antagonists for all primary aldosteronism patients to prevent target organ damage, irrespective of blood pressure control or serum potassium levels. Triggered when a clinician encounters a PA patient with well‑controlled BP and normal K and wonders, 'Do I still need to treat with MRA?' or considers stopping therapy.

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

Analisa os efeitos da revelia (CPC 344-346) e suas excecoes (345), tanto quando o cliente e o revel quanto quando a parte contraria e revel. Cobre a presuncao de veracidade dos fatos (344), as quatro hipoteses em que ela NAO opera (345 — litisconsorte contestante, direito indisponivel, falta de instrumento que a lei repute indispensavel, fatos inverossimeis/contraditorios com a prova), a fluencia de prazos sem intimacao (346) e a possibilidade de o revel ingressar e produzir prova. Use quando o operador disser revelia, reu revel, parte nao contestou, efeitos da revelia, presuncao de veracidade, ou meu cliente perdeu o prazo de defesa.

Use this skill when interpreting a drug test result that comes back as 'diluted negative,' 'diluted positive,' 'refusal,' or 'adulterated.' Covers what constitutes a refusal vs. retest vs. confirmed positive.

Fix PPO training early-stop issues. Trigger when: (1) impossible drawdown values (>100%), (2) training stops too early, (3) need adaptive recovery instead of hard stop.

Use this skill when the user asks about FCRA adverse action procedures — what to do when a background check (MVR, criminal, drug test) returns information that may lead to denying employment or terminating a CDL driver. Covers the 5-business-day pre-adverse-action notice, FCRA Summary of Rights, final adverse action notice, state-specific add-ons (CA, NY, etc.), and how to handle disputes. Cite 15 USC § 1681 (FCRA) and 49 CFR 391.

This skill guides clinicians in sharing decision‑making when selecting an antiepileptic drug (AED) by providing quantitative estimates of each drug’s expected weight effect. It is triggered when a clinician asks how to discuss weight‑change risks when choosing an AED or what information to provide on weight effects of specific agents such as valproate versus lamotrigine.

Electric neon glow effects with high-contrast color pairings for bold, attention-grabbing interfaces.

AI驱动的综合健康分析系统，整合多维度健康数据、识别异常模式、预测健康风险、提供个性化建议。支持智能问答和AI健康报告生成。

Bedside prescribing reference for Bemdec (bempedoic acid / NEXLETOL) — indication check, dose, statin co-prescribing safety caps, monitoring plan, warnings for hyperuricemia and tendon rupture, and special population guidance. Use when a clinician asks "can I start bempedoic acid", "Bemdec indication", "is bempedoic acid safe with my statin", "patient on Nexletol has joint pain or high uric acid", "bempedoic acid in CKD or liver disease or pregnancy", or any prescribing or monitoring question about bempedoic acid.

Burn HUD

Recommends weight‑losing and weight‑neutral medications as first‑ and second‑line agents for managing overweight/obese patients with type 2 diabetes. Triggers include when a clinician asks, 'Which diabetes medications will not worsen weight in this obese patient?' or 'Should I avoid sulfonylureas in this patient with T2DM and obesity due to weight gain risk?'

In patients with primary aldosteronism receiving mineralocorticoid receptor antagonist therapy, the guideline recommends titrating the MRA dose upward to raise renin when blood pressure remains uncontrolled and renin is suppressed. Consider this step when hypertension is not at goal despite MRA therapy and plasma renin activity (or direct renin concentration) is low.

v4.1.0 reward function redesign to fix overtrading and DSR dominance

Recommends using mineralocorticoid receptor antagonists rather than epithelial sodium-channel inhibitors for medical treatment of primary aldosteronism. Use when a clinician asks whether to use an MRA or ENaC inhibitor for medical treatment of PA.

Dizziness Red Flag Screener

Determines whether to add a mineralocorticoid receptor antagonist (e.g., spironolactone or eplerenone) to glucocorticoid therapy in glucocorticoid-remediable aldosteronism when blood pressure fails to normalize with glucocorticoid alone. Triggered by persistent hypertension or inadequate BP control despite optimized glucocorticoid dosing in GRA patients.

Recommends ACE inhibitors, ARBs, or calcium channel blockers as first-line hypertension therapy rather than β‑adrenergic blockers in obese patients with type 2 diabetes. Triggers include when a clinician asks, 'What antihypertensive should I start for this obese patient with T2DM to avoid weight gain?' or 'Should I avoid β‑blockers in this patient with diabetes and hypertension?'

Evaluates likelihood of primary aldosteronism by measuring plasma aldosterone suppression after oral captopril; normal suppression ≥30% makes PA unlikely, while lack of suppression with persistently suppressed plasma renin activity suggests PA. Use when assessing captopril challenge test (CCT) results for PA diagnosis in patients with positive aldosterone-to-renin ratio.

Econometrics skill for Difference-in-Differences (DID) analysis. Activates when the user asks about: "difference in differences", "DID", "DiD", "diff-in-diff", "parallel trends", "treatment group", "control group", "pre-treatment", "post-treatment", "policy evaluation", "natural experiment", "staggered DID", "event study regression", "two-way fixed effects DID", "callaway santanna", "sun and abraham", "双重差分", "倍差法", "平行趋势", "处理组", "对照组", "政策评估", "事件研究", "交错DID", "渐进处理"

Advises assessing efficacy and safety at least monthly for the first 3 months, then at least every 3 months for all patients prescribed weight‑loss medications. Triggers include clinician questions such as “How often should I check progress after starting orlistat?” or “What is the follow‑up schedule for a patient on liraglutide?”.

Recommends a shared decision‑making process that provides patients with quantitative estimates of the expected weight effect of antidepressants to inform drug choice, also considering expected treatment length. Triggers include clinician questions such as ‘How should I discuss weight‑change risks with this patient starting an antidepressant?’ or ‘What tool can I use to show expected weight impact of sertraline vs bupropion?’.

This skill suggests using approved weight‑loss medication over no pharmacological therapy to ameliorate comorbidities and improve physical activity in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one comorbid condition. It is triggered when a clinician asks, for example, 'Should I add medication to help maintain weight loss in this patient with BMI 31 and diabetes?' or 'Is pharmacotherapy appropriate for long‑term weight control in a patient with BMI 28 and hypertension?'.

Recommends administering stress-dose glucocorticoids before surgery and tapering after surgery in patients with adrenal insufficiency before repeat testing. Triggers include preoperative planning for surgery in a patient with known or suspected adrenal insufficiency.